Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS.

Clin Cancer Res. 2018 Nov 15;24(22):5552-5561. doi: 10.1158/1078-0432.CCR-18-0945. Epub 2018 Jul 25.

PMID:
30045932
2.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

3.

Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study.

Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, Morishima C, Hutchinson K, Mudgistratova L, Blom A, Iyer J, Moshiri AS, Tarabadkar ES, Carter JJ, Bhatia S, Kawasumi M, Galloway DA, Wener MH, Nghiem P.

Cancer. 2017 Apr 15;123(8):1464-1474. doi: 10.1002/cncr.30475. Epub 2016 Dec 7.

4.

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG.

Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3.

5.

A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.

Simons BC, Spradling PR, Bruden DJ, Zanis C, Case S, Choromanski TL, Apodaca M, Brogdon HD, Dwyer G, Snowball M, Negus S, Bruce MG, Morishima C, Knall C, McMahon BJ.

J Infect Dis. 2016 Jul 15;214(2):273-80. doi: 10.1093/infdis/jiw142. Epub 2016 Apr 7.

6.

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.

Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM.

PLoS One. 2016 Feb 29;11(2):e0148764. doi: 10.1371/journal.pone.0148764. eCollection 2016.

7.

Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infection.

Yu L, Morishima C, Ioannou GN.

Br J Nutr. 2016 Jan 28;115(2):193-201. doi: 10.1017/S0007114515004158. Epub 2015 Nov 6.

PMID:
26541123
8.

Dietary cholesterol intake is associated with progression of liver disease in patients with chronic hepatitis C: analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial.

Yu L, Morishima C, Ioannou GN.

Clin Gastroenterol Hepatol. 2013 Dec;11(12):1661-6.e1-3. doi: 10.1016/j.cgh.2013.05.018. Epub 2013 May 23.

PMID:
23707779
9.

Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.

Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC; HALT-C Trial Group.

Am J Gastroenterol. 2012 Sep;107(9):1388-98. doi: 10.1038/ajg.2012.137. Epub 2012 Jun 12.

10.

Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C.

Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC; HALT-C Trial Group.

J Viral Hepat. 2012 Jun;19(6):404-13. doi: 10.1111/j.1365-2893.2011.01562.x. Epub 2011 Dec 16.

11.

A summary of the 18th International Symposium on Hepatitis C Virus and Related Viruses.

Polyak SJ, Morishima C, Scott JD, Gastaminza P, Cox A, de Araújo ES, Higgs MR, Loo YM, Golden-Mason L, Lindenbach BD, Baumert TF, Randall G, Gale M Jr.

Gastroenterology. 2012 Jan;142(1):e1-5. doi: 10.1053/j.gastro.2011.11.002. No abstract available. Erratum in: Gastroenterology. 2012 Feb;142(2):411. Gastaminza, Pablo [added].

PMID:
22185796
12.

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group.

Hepatology. 2011 Aug;54(2):396-405. doi: 10.1002/hep.24370. Epub 2011 Jun 23.

13.

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.

Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; HALT-C Trial Group.

Hepatology. 2011 Apr;53(4):1100-8. doi: 10.1002/hep.24169.

14.

Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.

Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL; HALT-C Trial Group.

Gastroenterology. 2011 May;140(5):1490-500.e3. doi: 10.1053/j.gastro.2011.01.053. Epub 2011 Feb 15.

15.

Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.

Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, Tavis JE, Polyak SJ.

PLoS One. 2011 Jan 28;6(1):e16464. doi: 10.1371/journal.pone.0016464.

16.

Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.

Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group.

Gastroenterology. 2011 Mar;140(3):840-9; quiz e12. doi: 10.1053/j.gastro.2010.11.050. Epub 2010 Dec 1.

17.

Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial.

Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, Sinha R, Everhart JE; HALT-C Trial Group.

Aliment Pharmacol Ther. 2011 Jan;33(1):127-37. doi: 10.1111/j.1365-2036.2010.04503.x. Epub 2010 Nov 2.

18.

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; HALT-C Trial Group.

Hepatology. 2010 Sep;52(3):833-44. doi: 10.1002/hep.23744.

19.

Identification of hepatoprotective flavonolignans from silymarin.

Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5995-9. doi: 10.1073/pnas.0914009107. Epub 2010 Mar 15.

20.

Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ; HALT-C Trial Group.

Hepatology. 2010 Feb;51(2):585-94. doi: 10.1002/hep.23315.

21.

Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.

Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C; HALT-C Trial Group.

Hepatology. 2009 Dec;50(6):1738-49. doi: 10.1002/hep.23211.

22.

Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection.

Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, Sloan DD, Graf TN, Oberlies NH, Lee DY, Jerome KR, Polyak SJ.

Gastroenterology. 2010 Feb;138(2):671-81, 681.e1-2. doi: 10.1053/j.gastro.2009.09.021. Epub 2009 Sep 24.

23.

Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.

Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL; HALT-C Trial Group.

Gastroenterology. 2010 Jan;138(1):136-46. doi: 10.1053/j.gastro.2009.09.007. Epub 2009 Sep 18.

24.

Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group.

Gastroenterology. 2009 Dec;137(6):1986-94. doi: 10.1053/j.gastro.2009.08.067. Epub 2009 Sep 10. Erratum in: Gastroenterology. 2010 Mar;138(3):1215.

25.

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.

Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group.

Hepatology. 2009 Nov;50(5):1360-9. doi: 10.1002/hep.23162.

26.

Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.

Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1828-37. doi: 10.1002/hep.22865.

27.

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators.

N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.

28.

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial Group.

Gastroenterology. 2009 Jan;136(1):138-48. doi: 10.1053/j.gastro.2008.09.014. Epub 2008 Sep 18.

29.

Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.

Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM; HALT-C Trial Group.

Hepatology. 2008 Nov;48(5):1412-9. doi: 10.1002/hep.22487.

30.

Antiviral effects of silymarin against hepatitis C: the jury is still out.

Polyak SJ, Morishima C, Hawke R.

Hepatology. 2008 Jul;48(1):345-6. doi: 10.1002/hep.22235. No abstract available.

PMID:
18509876
31.

Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.

Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG; HALT-C Trial.

Clin Gastroenterol Hepatol. 2008 Feb;6(2):234-41. doi: 10.1016/j.cgh.2007.11.020.

PMID:
18237873
32.

Hepatitis C virus activation in HIV-infected patients initiating highly active antiretroviral therapy.

Kim HN, Harrington RD, Shuhart MC, Cook L, Morishima C, Jerome KR, Wang CC.

AIDS Patient Care STDS. 2007 Oct;21(10):718-23.

PMID:
17949270
33.

Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection.

Morishima C, Shuhart MC, Yoshihara CS, Paschal DM, Silva MA, Thomassen LV, Emerson SS, Gretch DR.

J Infect Dis. 2007 Aug 15;196(4):577-86. Epub 2007 Jun 28.

PMID:
17624844
34.

Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.

Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY.

Gastroenterology. 2007 May;132(5):1925-36. Epub 2007 Feb 21.

PMID:
17484885
35.

Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C; HALT-C Trial Group.

Clin Gastroenterol Hepatol. 2007 Feb;5(2):245-54.

PMID:
17296533
36.

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2006 Dec;44(6):1675-84.

37.

Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.

Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C; HALT-C Trial Group.

Gastroenterology. 2006 Nov;131(5):1440-51. Epub 2006 Aug 18.

PMID:
17101320
38.

HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.

Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR; HALT-C Trial Group.

Hepatology. 2006 Aug;44(2):360-7.

PMID:
16871570
39.

Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.

Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group.

J Infect Dis. 2006 Apr 1;193(7):931-40. Epub 2006 Feb 22.

PMID:
16518754
40.

Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing.

Morishima C, Paschal DM, Wang CC, Yoshihara CS, Wood BL, Yeo AE, Emerson SS, Shuhart MC, Gretch DR.

Hepatology. 2006 Mar;43(3):573-80.

PMID:
16496327
41.

High serum hepatitis C virus (HCV) RNA load predicts the presence of HCV RNA in saliva from individuals with chronic and acute HCV infection.

Wang CC, Morishima C, Chung M, Engelberg R, Krantz E, Krows M, Sullivan DG, Gretch DR, Corey L.

J Infect Dis. 2006 Mar 1;193(5):672-6. Epub 2006 Jan 27.

PMID:
16453262
42.

Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.

Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C.

Hepatology. 2005 Aug;42(2):282-92.

43.

Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis.

Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR; HALT-C Trial Group.

Virol J. 2005 Apr 22;2:41.

44.

Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C.

Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ; HALT-C Trial Group.

Hepatology. 2005 Mar;41(3):617-25.

PMID:
15726656
45.

Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE; HALT-C Trial Group.

Control Clin Trials. 2004 Oct;25(5):472-92.

PMID:
15465617
46.
47.

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group.

Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947.

PMID:
15057741
48.

Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.

Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR.

J Clin Microbiol. 2004 Jan;42(1):421-5.

49.

Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy.

Morishima C, Musey L, Elizaga M, Gaba K, Allison M, Carithers RL, Gretch DR, McElrath MJ.

Clin Immunol. 2003 Sep;108(3):211-20.

PMID:
14499244
50.

Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study.

Murray KF, Richardson LP, Morishima C, Owens JW, Gretch DR.

Pediatrics. 2003 Jan;111(1):153-7.

PMID:
12509569

Supplemental Content

Loading ...
Support Center